IMGN News and Press, ImmunoGen Inc. From 03/31/22

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccor...

ImmunoGen (NASDAQ:IMGN) submitted an application under the accelerated approval pathway to the U.S. Food and Drug Administration (FDA) for mirvetuximab soravtansine as standalone therapy for patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have previ...

Submission Based on Positive Results from Pivotal Phase 3 SORAYA Trial ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has submitted a Biologics License Application (B...

Following sharp gains throughout most of last week, investors took a more cautious stance on Monday, sending the major averages modestly lower. E-commerce stocks epitomized the recent trading activity, losing ground during the session after substantial gains in the previous few sessions. Shop...

The stock market showed its mettle last week, with solid gains for major indexes. However, the momentum didn't last very far into Monday, and midday comments from Fed chair Jerome Powell left the Nasdaq Composite (NASDAQINDEX: ^IXIC) down more than 1.5% as of 1:30 p.m. ET. Last ...

Gainers: NeuroSense (NRSN) +333%. BitNile (NILE) +69%. Yumanity Therapeutics (YMTX) +50%. BT Brands (BTBD) +41%. Mullen Automotive (MULN) +39%. Hudson Capital (HUSN) +38%. O2Micro International (OIIM) +32%. Cenntro Electric Group (CENN) +33%. Akanda (AKAN) +29%. Anaplan (PLAN) +28%. Losers: V...

Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...

Shares of ImmunoGen (NASDAQ:IMGN) are down 18% in premarket trading after the biotech presented final results from a pivotal trial of mirvetuximab in platinum-resistant ovarian cancer. The trial met its primary endpoint of confirmed objective response rate ("ORR") of 32.4%. The...

Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9 Months Mirvetuximab Demonstrated Meaningful Anti-Tumor Activity, Consistent Safety, and Favorable Tolerability in FRα-H...

Data from Pivotal Trial to be Highlighted in Oral Presentation on Saturday, March 19 Investor Event to be Held Sunday, March 20 at 7:30 am MST ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of ...